1. Phylogeny  
   Tyrosine‐protein kinase JAK3 (UniProt ID: P52333), also known as Janus kinase 3 or Leukocyte janus kinase, is a member of the larger Janus kinase family of non‐receptor tyrosine kinases within the tyrosine kinase (TK) group of the human kinome. Phylogenetic analyses using advanced classification systems such as KinFams have revealed that the catalytic domain of JAK3 is highly conserved among its family members—including JAK1, JAK2, and TYK2—while simultaneously exhibiting distinct specificity‐determining residues that are linked to its specialized roles (adeyelu2023kinfamsdenovoclassification pages 1-2). Although all JAK paralogs share a common domain architecture, JAK3 is unique in that its expression is largely confined to hematopoietic cells, particularly lymphoid lineages, which reflects its specialized function in immune regulation. Orthologs of JAK3 have been identified in various vertebrate species including numerous mammals, underscoring its evolutionary importance in the establishment and regulation of adaptive immunity (liongue2024januskinase3 pages 1-3). While JAK1 is broadly expressed and involved in multiple cytokine receptor signaling cascades, evolutionary divergence has resulted in JAK3 developing an immune‐restricted expression pattern that is critical for lymphoid cell development and function (negi2021recentadvancesin pages 2-4). More detailed phylogenetic reconstructions indicate that the Janus kinase family emerged early in vertebrate evolution, concomitant with the evolution of cytokine signaling pathways, and that the expansion of JAK members has been coupled with the increasing complexity of the immune system (adeyelu2023kinfamsdenovoclassification pages 1-2).
2. Reaction Catalyzed  
   JAK3 functions as an ATP-dependent non-receptor tyrosine kinase in receptor-mediated signaling pathways. The central chemical reaction catalyzed by JAK3 is the phosphorylation of specific tyrosine residues on substrate proteins—a process essential for the propagation of intracellular signals. In this phosphoryl-transfer reaction, the enzyme binds ATP within its catalytic cleft and directs the transfer of the γ-phosphate group from ATP to the hydroxyl group of a tyrosine residue on its protein substrate. The principal physiological substrates for JAK3 include the cytoplasmic tails of type I cytokine receptors that share the common gamma chain (IL2RG), such as those receptors for interleukins IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, as well as key signaling proteins like STAT5A and STAT5B (gao2018jakstatsignaltransduction pages 10-11, liongue2024januskinase3 pages 1-3). The reaction can be described stoichiometrically as:  
     ATP + [Protein]-Tyr → ADP + [Protein]-pTyr + H⁺  
   During this process, the JH1 kinase domain assembles the reaction complex by binding ATP within a deep, bilobal cleft between its N-lobe (rich in β‐sheets) and C-lobe (predominantly α-helical), thus providing the structural framework that enables the catalytic residues (such as the conserved lysine from the β3 strand and an aspartate from the HRD motif) to coordinate ATP and orient the substrate tyrosine for optimal phosphoryl transfer (zhu2019molecularrecognitionof pages 44-49, raivolaUnknownyearmolecularregulationof pages 19-23). By phosphorylating receptor tails, JAK3 creates phosphotyrosine docking motifs that serve to recruit STAT proteins, which are then phosphorylated further to permit dimerization and nuclear translocation, ultimately leading to the transcriptional regulation of genes that govern lymphocyte development and function.
3. Cofactor Requirements  
   The kinase activity of JAK3 is intrinsically linked to its ATP-binding capacity, and like many canonical protein kinases, its catalytic mechanism is enhanced by the presence of metal ion cofactors. In the active kinase domain (JH1), the binding of ATP is classically coordinated by divalent metal ions—most notably magnesium (Mg²⁺). Mg²⁺ interacts with the phosphate groups of ATP, typically via coordination with the aspartate residue of the DFG motif, thereby stabilizing the ATP moiety in the active site and facilitating the efficient transfer of the γ-phosphate to the substrate tyrosine (hu2021thejakstatsignaling pages 2-3). However, JAK3 also possesses an adjacent pseudokinase domain known as JH2, which, despite its limited catalytic activity, plays an essential regulatory role. Uniquely, biochemical studies have shown that the JH2 domain of JAK3 binds ATP in a manner that is independent of divalent metal ions, representing a clear contrast with the metal-dependent ATP coordination observed in the JH1 domain and in many other conventional kinases (grant2023jak1pseudokinasev666g pages 53-57, raivola2018hyperactivationofoncogenic pages 8-10). This cation-independent nucleotide binding within the pseudokinase domain is attributed to specific amino acid substitutions that compensate for the need for metal coordination, and it may serve as a regulatory module that influences the overall activation state and autoinhibition of JAK3. Thus, while Mg²⁺ is critical for the catalytic phosphoryl-transfer function of the JH1 domain, the JH2 domain employs a distinct mechanism for ATP binding that does not rely on metal ion cofactors, suggesting specialized roles for each domain in the modulation of kinase activity (hu2021thejakstatsignaling pages 2-3, grant2023jak1pseudokinasev666g pages 53-57).
4. Substrate Specificity  
   JAK3 displays a well-defined substrate specificity that is central to its role in cytokine receptor signaling. The enzyme primarily phosphorylates specific tyrosine residues located on the intracellular domains of type I cytokine receptors that share the common gamma chain, including receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 (gao2018jakstatsignaltransduction pages 10-11, liongue2024januskinase3 pages 1-3). Upon cytokine stimulation, these receptors undergo conformational rearrangements that expose tyrosine residues embedded within sequence contexts that are recognized by JAK3. Although a single, definitive consensus motif for JAK3 phosphorylation has not been universally agreed upon, studies employing combinatorial peptide library screens and extensive phosphoproteomic techniques indicate that the sequence environment of the target tyrosine often features a combination of acidic and hydrophobic residues that promote high-affinity interactions with the surface of the kinase domain (yaronbarir2024theintrinsicsubstrate pages 1-2). Furthermore, detailed substrate specificity profiling using high-throughput in vitro analyses has revealed that, among the human tyrosine kinome, JAK3’s substrate recognition motif is distinct from its closely related family members such as JAK1, JAK2, and TYK2, emphasizing the evolutionary divergence in functional roles even within closely related kinases (yaronbarir2024theintrinsicsubstrate pages 10-11). This selective phosphorylation not only initiates the recruitment of STAT transcription factors by creating precise phosphotyrosine-based docking sites but also ensures that downstream signaling cascades occur with high fidelity, thereby tightly regulating the cellular responses to cytokine engagement.
5. Structure  
   The functional versatility of JAK3 is underpinned by its multidomain architecture, which integrates receptor binding, regulatory control, and catalytic activity within a single polypeptide chain. At the N-terminus, JAK3 contains a FERM (Band 4.1, Ezrin, Radixin, Moesin) domain that is primarily responsible for the binding of the kinase to the intracellular segments of cytokine receptors. This localization is crucial for the effective capture and transduction of extracellular cytokine signals (liongue2024januskinase3 pages 1-3, kwon2022moleculardissectionof pages 1-2). Adjacent to the FERM domain is an SH2-like domain that, while distinct from the canonical SH2 domain found in other signaling proteins, contributes to the stabilization of receptor interactions and proper spatial positioning within signaling complexes. Following these receptor-binding modules, JAK3 harbors a pseudokinase domain (JH2), which, despite lacking robust catalytic activity, functions as a critical regulatory element by modulating the activity of the downstream catalytic kinase domain (JH1) (grant2023jak1pseudokinasev666g pages 53-57, raivolaUnknownyearmolecularregulationof pages 105-107).  
   The C-terminal kinase domain (JH1) is responsible for the enzymatic activity of JAK3 and exhibits the classical bilobal structure common to eukaryotic protein kinases. The N-lobe of JH1 is predominantly composed of β-sheets and includes a conserved glycine-rich loop involved in ATP binding, while the larger C-lobe is mainly α-helical and contains the activation loop (A-loop) that undergoes conformational changes upon phosphorylation (zhu2019molecularrecognitionof pages 44-49). Key catalytic residues include a lysine in the β3 strand that is essential for coordinating ATP, an aspartate within the HRD motif that acts as the catalytic base, and the DFG motif that is pivotal for binding magnesium ions necessary for catalysis (hu2021thejakstatsignaling pages 2-3). Recent AI-guided modeling and crystallographic studies, as integrated within modern classification frameworks like KinFams, have provided high-resolution structural models that further elucidate the spatial arrangement of these domains and the interdomain contacts—particularly between the regulatory JH2 and the catalytic JH1—that are essential for maintaining the balance between autoinhibition and activation (mingione2023allostericregulationand pages 1-3, adeyelu2023kinfamsdenovoclassification pages 2-4). These structural insights are crucial for understanding how conformational dynamics and domain-domain interactions in JAK3 facilitate the transition from an inactive to an active signaling state upon cytokine receptor engagement.
6. Regulation  
   The activity of JAK3 is finely tuned by an array of regulatory mechanisms that encompass both intrinsic and extrinsic factors, ensuring that its signaling output is precisely controlled under physiological conditions. One key regulatory mechanism is the autoinhibitory function of the pseudokinase domain (JH2), which in the basal state interacts with the catalytic kinase domain (JH1) to suppress unwarranted activity. This autoinhibitory interaction is disrupted upon cytokine binding to the extracellular domains of receptors, leading to receptor dimerization or oligomerization that brings multiple JAK molecules into close proximity. The resulting structural rearrangements facilitate trans-phosphorylation of activation-loop tyrosine residues in the JH1 domains, thereby stabilizing the kinase in its active conformation (raivolaUnknownyearmolecularregulationof pages 105-107, tomoni2019pseudokinasesfromallosteric pages 10-13).  
   Post-translational modifications (PTMs) further modulate JAK3 function. Phosphorylation is a central PTM that both activates and regulates the enzyme; phosphorylation of tyrosines in the activation loop of the JH1 domain is essential for full kinase activity (gao2018jakstatsignaltransduction pages 10-11). In addition, there are regulatory phosphorylation events on other key residues that may influence intramolecular interactions and the conformational dynamics of the kinase (raivolaUnknownyearmolecularregulationof pages 118-126). Beyond phosphorylation, ubiquitination serves as a pivotal mechanism for the downregulation and degradation of JAK3. Specific E3 ubiquitin ligases target activated JAK3 or its receptor-associated complexes to mark the kinase for proteasomal degradation, thus ensuring that signal transduction is terminated when appropriate (negi2021recentadvancesin pages 2-4, raivolaUnknownyearmolecularregulationof pages 56-60).  
   Extrinsic negative feedback regulators such as the Suppressor of Cytokine Signaling (SOCS) proteins are also instrumental in downregulating JAK3 activity. SOCS proteins bind directly to JAK3 or its associated receptors and inhibit kinase activity by either blocking substrate access or promoting ubiquitination and subsequent proteasomal degradation of JAK3 (gadina2018translationalandclinical pages 2-3, raivolaUnknownyearmolecularregulationof pages 56-60). In addition, allosteric regulatory mechanisms are evident whereby ligand-induced conformational shifts in receptor complexes relieve the inhibitory hold of the JH2 domain on the catalytic JH1 domain, thereby facilitating a rapid and robust activation of downstream signaling pathways (grant2023jak1pseudokinasev666g pages 53-57, tomoni2019pseudokinasesfromallosteric pages 10-13). Overall, the multilayered regulation of JAK3—spanning intrinsic domain interactions, PTMs, and extrinsic inhibitors—ensures tight control over its function in response to extracellular cues, thereby preventing aberrant signaling that could lead to immune dysregulation.
7. Function  
   JAK3 plays an indispensable role in immune cell signaling due to its restricted expression in hematopoietic and lymphoid cells and its involvement in signaling pathways mediated by type I cytokine receptors that share the common gamma chain (IL2RG). Upon cytokine stimulation, such as by interleukins IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, JAK3 is recruited to receptor complexes via its N-terminal FERM and SH2-like domains, where it participates in the formation and stabilization of receptor-JAK heterodimers (often with JAK1) (gadina2018translationalandclinical pages 2-3, gadina2019januskinasesto pages 3-4). Once activated through trans-phosphorylation events between receptor-bound JAK molecules, JAK3 phosphorylates specific tyrosine residues within the cytoplasmic domains of these receptors. This phosphorylation creates high-affinity docking sites for STAT transcription factors, particularly STAT5A and STAT5B in the context of IL-2 receptor signaling (gao2018jakstatsignaltransduction pages 10-11).  
   Following its recruitment, STAT proteins become phosphorylated either by JAK3 itself or through cooperative action with JAK1, leading to STAT dimerization, nuclear translocation, and subsequent regulation of gene transcription. The genes activated by STATs govern critical cellular processes such as cell proliferation, differentiation, survival, and immune responses, thereby positioning JAK3 as a central mediator in both innate and adaptive immunity (gadina2019januskinasesto pages 3-4, liongue2024januskinase3 pages 1-3). In addition, the precise regulation of JAK3 function is vital for hematopoiesis, particularly during T-cell development, where its activity ensures proper maturation and differentiation of lymphoid cells. Mutations in JAK3 that result in either loss-of-function or gain-of-function effects have significant clinical implications: loss-of-function mutations are primarily associated with severe combined immunodeficiency (SCID), whereas gain-of-function mutations can lead to aberrant, constitutive kinase activation and contribute to the development of hematologic malignancies (raivola2018hyperactivationofoncogenic pages 1-2, gadina2019januskinasesto pages 3-4). Therefore, the role of JAK3 in orchestrating cytokine receptor signaling underscores its importance in immune cell homeostasis, and it remains a highly attractive target for therapeutic intervention in immunological and hematological disorders.
8. Other Comments  
   Given its critical role in immune regulation and its restricted expression within hematopoietic cells, JAK3 is the focus of intense drug discovery efforts. The development of selective JAK3 inhibitors is driven by the need to target aberrant signaling in autoimmune diseases and certain lymphoid malignancies while minimizing off-target effects commonly associated with pan-JAK inhibition. Several small-molecule inhibitors have been designed to exploit the unique structural features of JAK3, particularly the distinct architecture of its ATP-binding pocket and the regulatory attributes of its pseudokinase (JH2) domain (remenyi2021generationofa pages 12-13, mingione2023allostericregulationand pages 1-3). Some of these inhibitors take advantage of covalent binding mechanisms directed at specific cysteine residues unique to JAK3, which can enhance inhibitor selectivity and potency. In addition, ongoing research focuses on understanding the interplay between the regulatory JH2 and catalytic JH1 domains, as alterations in these regions—whether through naturally occurring mutations or via engineered inhibitors—can significantly affect the balance between autoinhibition and activation. Novel approaches leveraging cryo-electron microscopy and AI-driven structural predictions are providing unprecedented insights into the conformational dynamics of JAK3, paving the way for next-generation therapeutics that target allosteric sites and other regulatory interfaces (ott2023jaksandstats pages 20-21, remenyi2021generationofa pages 12-13).  
   Furthermore, due to the dual role of JAK3 in both promoting normal immune function and contributing to pathological states when dysregulated, there is considerable interest in stratifying patients based on specific JAK3 mutations. Loss-of-function mutations typically manifest clinically as SCID, which has been successfully treated via hematopoietic stem cell transplantation; in contrast, gain-of-function mutations that lead to constitutive activation of JAK3 are investigated as potential drivers of leukemogenesis and other hematologic cancers (raivola2018hyperactivationofoncogenic pages 1-2, gadina2019januskinasesto pages 3-4). The therapeutic potential of targeting JAK3 with selective inhibitors is enhanced by its immune-specific expression, which raises the promise of interventions that modulate cytokine signaling exclusively in immune cells, thereby reducing systemic toxicity. These endeavors are supported by comprehensive kinase classification initiatives such as KinFams, which provide a detailed framework for understanding the structural and functional nuances of JAK3 in comparison with other kinases (adeyelu2023kinfamsdenovoclassification pages 16-18). Overall, the balance between activation and inhibition in JAK3—dictated by intricate domain interactions and regulatory mechanisms—remains a central theme in current research aimed at exploiting this kinase for therapeutic gain.
9. References  
   adeyelu2023kinfamsdenovoclassification pages 1-2, adeyelu2023kinfamsdenovoclassification pages 2-4, adeyelu2023kinfamsdenovoclassification pages 16-18, caveney2023structuralbasisof pages 13-19, gadina2018translationalandclinical pages 2-3, gadina2019januskinasesto pages 3-4, gao2018jakstatsignaltransduction pages 10-11, grant2023jak1pseudokinasev666g pages 53-57, hu2021thejakstatsignaling pages 2-3, kwon2022moleculardissectionof pages 1-2, liongue2024januskinase3 pages 1-3, liongue2024januskinase3 pages 3-4, mingione2023allostericregulationand pages 1-3, negi2021recentadvancesin pages 2-4, ott2023jaksandstats pages 20-21, ott2023jaksandstats pages 21-22, raivola2018hyperactivationofoncogenic pages 1-2, raivola2018hyperactivationofoncogenic pages 2-3, raivola2018hyperactivationofoncogenic pages 4-7, raivola2018hyperactivationofoncogenic pages 8-10, raivolaUnknownyearmolecularregulationof pages 105-107, raivolaUnknownyearmolecularregulationof pages 118-126, raivolaUnknownyearmolecularregulationof pages 128-130, raivolaUnknownyearmolecularregulationof pages 132-134, raivolaUnknownyearmolecularregulationof pages 14-19, raivolaUnknownyearmolecularregulationof pages 19-23, reys2022insilicoprofiling pages 32-35, remenyi2021generationofa pages 1-2, remenyi2021generationofa pages 12-13, tomoni2019pseudokinasesfromallosteric pages 10-13, yaronbarir2024theintrinsicsubstrate pages 1-2, yaronbarir2024theintrinsicsubstrate pages 10-11, zhu2019molecularrecognitionof pages 44-49

References

1. (adeyelu2023kinfamsdenovoclassification pages 1-2): Tolulope Adeyelu, Nicola Bordin, Vaishali P. Waman, Marta Sadlej, Ian Sillitoe, Aurelio A. Moya-Garcia, and Christine A. Orengo. Kinfams: de-novo classification of protein kinases using cath functional units. Biomolecules, 13:277, Feb 2023. URL: https://doi.org/10.3390/biom13020277, doi:10.3390/biom13020277. This article has 8 citations and is from a peer-reviewed journal.
2. (caveney2023structuralbasisof pages 13-19): Nathanael A. Caveney, Robert A. Saxton, Deepa Waghray, Caleb R. Glassman, Naotaka Tsutsumi, Stevan R. Hubbard, and K. Christopher Garcia. Structural basis of janus kinase trans-activation. Cell Reports, 42:112201, Mar 2023. URL: https://doi.org/10.1016/j.celrep.2023.112201, doi:10.1016/j.celrep.2023.112201. This article has 34 citations and is from a highest quality peer-reviewed journal.
3. (gadina2018translationalandclinical pages 2-3): Massimo Gadina, Catrina Johnson, Daniella Schwartz, Michael Bonelli, Sarfaraz Hasni, Yuka Kanno, Paul Changelian, Arian Laurence, and John J O’Shea. Translational and clinical advances in jak-stat biology: the present and future of jakinibs. Journal of Leukocyte Biology, 104:499-514, Jul 2018. URL: https://doi.org/10.1002/jlb.5ri0218-084r, doi:10.1002/jlb.5ri0218-084r. This article has 169 citations and is from a peer-reviewed journal.
4. (gadina2019januskinasesto pages 3-4): Massimo Gadina, Mimi T Le, Daniella M Schwartz, Olli Silvennoinen, Shingo Nakayamada, Kunihiro Yamaoka, and John J O’Shea. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology, 58:i4-i16, Feb 2019. URL: https://doi.org/10.1093/rheumatology/key432, doi:10.1093/rheumatology/key432. This article has 168 citations and is from a peer-reviewed journal.
5. (gao2018jakstatsignaltransduction pages 10-11): Qianwen Gao, Xuewu Liang, Abdul Sami Shaikh, Jie Zang, Wenfang Xu, and Yingjie Zhang. Jak/stat signal transduction: promising attractive targets for immune, inflammatory and hematopoietic diseases. Current Drug Targets, 19:487-500, Mar 2018. URL: https://doi.org/10.2174/1389450117666161207163054, doi:10.2174/1389450117666161207163054. This article has 79 citations and is from a peer-reviewed journal.
6. (grant2023jak1pseudokinasev666g pages 53-57): Alice H. Grant, Alejandro C. Rodriguez, Omar J. Rodriguez Moncivais, Shengjie Sun, Lin Li, Jonathon E. Mohl, Ming-Ying Leung, Robert A. Kirken, and Georgialina Rodriguez. Jak1 pseudokinase v666g mutant dominantly impairs jak3 phosphorylation and il-2 signaling. International Journal of Molecular Sciences, 24:6805, Apr 2023. URL: https://doi.org/10.3390/ijms24076805, doi:10.3390/ijms24076805. This article has 8 citations and is from a peer-reviewed journal.
7. (hu2021thejakstatsignaling pages 2-3): Xiaoyi Hu, Jing li, Maorong Fu, Xia Zhao, and Wei Wang. The jak/stat signaling pathway: from bench to clinic. Signal Transduction and Targeted Therapy, Nov 2021. URL: https://doi.org/10.1038/s41392-021-00791-1, doi:10.1038/s41392-021-00791-1. This article has 1817 citations and is from a peer-reviewed journal.
8. (kwon2022moleculardissectionof pages 1-2): Sunghark Kwon. Molecular dissection of janus kinases as drug targets for inflammatory diseases. Frontiers in Immunology, Dec 2022. URL: https://doi.org/10.3389/fimmu.2022.1075192, doi:10.3389/fimmu.2022.1075192. This article has 13 citations and is from a peer-reviewed journal.
9. (liongue2024januskinase3 pages 1-3): Clifford Liongue, Tarindhi Ratnayake, Faiza Basheer, and Alister C. Ward. Janus kinase 3 (jak3): a critical conserved node in immunity disrupted in immune cell cancer and immunodeficiency. International Journal of Molecular Sciences, 25:2977, Mar 2024. URL: https://doi.org/10.3390/ijms25052977, doi:10.3390/ijms25052977. This article has 6 citations and is from a peer-reviewed journal.
10. (liongue2024januskinase3 pages 3-4): Clifford Liongue, Tarindhi Ratnayake, Faiza Basheer, and Alister C. Ward. Janus kinase 3 (jak3): a critical conserved node in immunity disrupted in immune cell cancer and immunodeficiency. International Journal of Molecular Sciences, 25:2977, Mar 2024. URL: https://doi.org/10.3390/ijms25052977, doi:10.3390/ijms25052977. This article has 6 citations and is from a peer-reviewed journal.
11. (mingione2023allostericregulationand pages 1-3): Victoria R. Mingione, YiTing Paung, Ian R. Outhwaite, and Markus A. Seeliger. Allosteric regulation and inhibition of protein kinases. Biochemical Society Transactions, 51:373-385, Feb 2023. URL: https://doi.org/10.1042/bst20220940, doi:10.1042/bst20220940. This article has 19 citations and is from a peer-reviewed journal.
12. (negi2021recentadvancesin pages 2-4): Preeya Negi, Rameshwar S. Cheke, and Vaishali M. Patil. Recent advances in pharmacological diversification of src family kinase inhibitors. Egyptian Journal of Medical Human Genetics, Jun 2021. URL: https://doi.org/10.1186/s43042-021-00172-x, doi:10.1186/s43042-021-00172-x. This article has 22 citations and is from a peer-reviewed journal.
13. (ott2023jaksandstats pages 20-21): Nils Ott, Laura Faletti, Maximilian Heeg, Virginia Andreani, and Bodo Grimbacher. Jaks and stats from a clinical perspective: loss-of-function mutations, gain-of-function mutations, and their multidimensional consequences. Journal of Clinical Immunology, 43:1326-1359, May 2023. URL: https://doi.org/10.1007/s10875-023-01483-x, doi:10.1007/s10875-023-01483-x. This article has 48 citations and is from a domain leading peer-reviewed journal.
14. (ott2023jaksandstats pages 21-22): Nils Ott, Laura Faletti, Maximilian Heeg, Virginia Andreani, and Bodo Grimbacher. Jaks and stats from a clinical perspective: loss-of-function mutations, gain-of-function mutations, and their multidimensional consequences. Journal of Clinical Immunology, 43:1326-1359, May 2023. URL: https://doi.org/10.1007/s10875-023-01483-x, doi:10.1007/s10875-023-01483-x. This article has 48 citations and is from a domain leading peer-reviewed journal.
15. (raivola2018hyperactivationofoncogenic pages 1-2): Juuli Raivola, Henrik M. Hammarén, Anniina T. Virtanen, Vilasha Bulleeraz, Alister C. Ward, and Olli Silvennoinen. Hyperactivation of oncogenic jak3 mutants depend on atp binding to the pseudokinase domain. Frontiers in Oncology, Dec 2018. URL: https://doi.org/10.3389/fonc.2018.00560, doi:10.3389/fonc.2018.00560. This article has 19 citations and is from a peer-reviewed journal.
16. (raivola2018hyperactivationofoncogenic pages 2-3): Juuli Raivola, Henrik M. Hammarén, Anniina T. Virtanen, Vilasha Bulleeraz, Alister C. Ward, and Olli Silvennoinen. Hyperactivation of oncogenic jak3 mutants depend on atp binding to the pseudokinase domain. Frontiers in Oncology, Dec 2018. URL: https://doi.org/10.3389/fonc.2018.00560, doi:10.3389/fonc.2018.00560. This article has 19 citations and is from a peer-reviewed journal.
17. (raivola2018hyperactivationofoncogenic pages 4-7): Juuli Raivola, Henrik M. Hammarén, Anniina T. Virtanen, Vilasha Bulleeraz, Alister C. Ward, and Olli Silvennoinen. Hyperactivation of oncogenic jak3 mutants depend on atp binding to the pseudokinase domain. Frontiers in Oncology, Dec 2018. URL: https://doi.org/10.3389/fonc.2018.00560, doi:10.3389/fonc.2018.00560. This article has 19 citations and is from a peer-reviewed journal.
18. (raivola2018hyperactivationofoncogenic pages 8-10): Juuli Raivola, Henrik M. Hammarén, Anniina T. Virtanen, Vilasha Bulleeraz, Alister C. Ward, and Olli Silvennoinen. Hyperactivation of oncogenic jak3 mutants depend on atp binding to the pseudokinase domain. Frontiers in Oncology, Dec 2018. URL: https://doi.org/10.3389/fonc.2018.00560, doi:10.3389/fonc.2018.00560. This article has 19 citations and is from a peer-reviewed journal.
19. (raivolaUnknownyearmolecularregulationof pages 105-107): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
20. (raivolaUnknownyearmolecularregulationof pages 118-126): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
21. (raivolaUnknownyearmolecularregulationof pages 128-130): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
22. (raivolaUnknownyearmolecularregulationof pages 132-134): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
23. (raivolaUnknownyearmolecularregulationof pages 14-19): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
24. (raivolaUnknownyearmolecularregulationof pages 19-23): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
25. (raivolaUnknownyearmolecularregulationof pages 56-60): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
26. (remenyi2021generationofa pages 1-2): Judit Remenyi, Rangeetha Jayaprakash Naik, Jinhua Wang, Momchil Razsolkov, Alyssa Verano, Quan Cai, Li Tan, Rachel Toth, Samantha Raggett, Carla Baillie, Ryan Traynor, C. James Hastie, Nathanael S. Gray, and J. Simon C. Arthur. Generation of a chemical genetic model for jak3. Scientific Reports, May 2021. URL: https://doi.org/10.1038/s41598-021-89356-4, doi:10.1038/s41598-021-89356-4. This article has 6 citations and is from a poor quality or predatory journal.
27. (remenyi2021generationofa pages 12-13): Judit Remenyi, Rangeetha Jayaprakash Naik, Jinhua Wang, Momchil Razsolkov, Alyssa Verano, Quan Cai, Li Tan, Rachel Toth, Samantha Raggett, Carla Baillie, Ryan Traynor, C. James Hastie, Nathanael S. Gray, and J. Simon C. Arthur. Generation of a chemical genetic model for jak3. Scientific Reports, May 2021. URL: https://doi.org/10.1038/s41598-021-89356-4, doi:10.1038/s41598-021-89356-4. This article has 6 citations and is from a poor quality or predatory journal.
28. (reys2022insilicoprofiling pages 32-35): V Reys. In silico profiling of protein-kinases inhibitors and study of protein-protein interactions. Unknown journal, 2022.
29. (tomoni2019pseudokinasesfromallosteric pages 10-13): Andrada Tomoni, Jonathan Lees, Andrés G. Santana, Victor M. Bolanos-Garcia, and Agatha Bastida. Pseudokinases: from allosteric regulation of catalytic domains and the formation of macromolecular assemblies to emerging drug targets. Catalysts, 9:778, Sep 2019. URL: https://doi.org/10.3390/catal9090778, doi:10.3390/catal9090778. This article has 19 citations and is from a peer-reviewed journal.
30. (yaronbarir2024theintrinsicsubstrate pages 1-2): Tomer M. Yaron-Barir, Brian A. Joughin, Emily M. Huntsman, Alexander Kerelsky, Daniel M. Cizin, Benjamin M. Cohen, Amit Regev, Junho Song, Neil Vasan, Ting-Yu Lin, Jose M. Orozco, Christina Schoenherr, Cari Sagum, Mark T. Bedford, R. Max Wynn, Shih-Chia Tso, David T. Chuang, Lei Li, Shawn S.-C. Li, Pau Creixell, Konstantin Krismer, Mina Takegami, Harin Lee, Bin Zhang, Jingyi Lu, Ian Cossentino, Sean D. Landry, Mohamed Uduman, John Blenis, Olivier Elemento, Margaret C. Frame, Peter V. Hornbeck, Lewis C. Cantley, Benjamin E. Turk, Michael B. Yaffe, and Jared L. Johnson. The intrinsic substrate specificity of the human tyrosine kinome. Nature, 629:1174-1181, May 2024. URL: https://doi.org/10.1038/s41586-024-07407-y, doi:10.1038/s41586-024-07407-y. This article has 50 citations and is from a highest quality peer-reviewed journal.
31. (zhu2019molecularrecognitionof pages 44-49): Y Zhu. Molecular recognition of protein kinase inhibitors: a data mining and advanced quantum chemical study. Unknown journal, 2019.
32. (adeyelu2023kinfamsdenovoclassification pages 16-18): Tolulope Adeyelu, Nicola Bordin, Vaishali P. Waman, Marta Sadlej, Ian Sillitoe, Aurelio A. Moya-Garcia, and Christine A. Orengo. Kinfams: de-novo classification of protein kinases using cath functional units. Biomolecules, 13:277, Feb 2023. URL: https://doi.org/10.3390/biom13020277, doi:10.3390/biom13020277. This article has 8 citations and is from a peer-reviewed journal.
33. (adeyelu2023kinfamsdenovoclassification pages 2-4): Tolulope Adeyelu, Nicola Bordin, Vaishali P. Waman, Marta Sadlej, Ian Sillitoe, Aurelio A. Moya-Garcia, and Christine A. Orengo. Kinfams: de-novo classification of protein kinases using cath functional units. Biomolecules, 13:277, Feb 2023. URL: https://doi.org/10.3390/biom13020277, doi:10.3390/biom13020277. This article has 8 citations and is from a peer-reviewed journal.